Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 4/20 | 0.43 |
| ▸ | CA1 | P00915 | 4/20 | 0.43 |
| ▸ | CA9 | Q16790 | 4/20 | 0.43 |
| ▸ | PREP | P48147 | 4/20 | 0.35 |
| ▸ | HSP90AA1 | P07900 | 2/20 | 0.34 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29951222 | 1.00 | CA12 (0.43) | CA12CA1CA9PREPHSP90AA1 | |
| SCHEMBL2022605 | 0.82 | CA12 (0.44) | CA12CA1CA9PREPHSP90AA1 | |
| SCHEMBL29951251 | 0.79 | CA1 (0.42) | CA12CA1CA9PREPHSP90AA1 | |
| SCHEMBL2025934 | 0.79 | CA1 (0.42) | CA12CA1CA9PREPHSP90AA1 | |
| SCHEMBL12577662 | 0.79 | CA12 (0.44) | CA12CA1CA9PREPHSP90AA1 | |
| SCHEMBL17836741 | 0.78 | CA12 (0.46) | CA12CA1CA9PREPHSP90AA1 | |
| SCHEMBL17593129 | 0.77 | CA12 (0.43) | CA12CA1CA9PREPHSP90AA1 | |
| SCHEMBL24455832 | 0.77 | CA12 (0.45) | CA12CA1CA9PREPHSP90AA1 | |
| SCHEMBL20535255 | 0.77 | CA12 (0.45) | CA12CA1CA9PREPHSP90AA1 | |
| SCHEMBL29653234 | 0.77 | CA12 (0.45) | CA12CA1CA9PREPHSP90AA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118076348-A | N-acylhydrazone compounds capable of inhibiting NAV 1.7 and/or NAV 1.8, methods of making, compositions, uses, methods of treatment and kits using the same | 欧罗法玛实验室股份公司 | 2024-05-24 | — | — | CN | disclosed |
| WO-2023010191-A1 | N-ACYLHYDRAZONE COMPOUNDS CAPABLE OF INHIBITING NAV1.7 AND/OR NAV1.8, PROCESSES FOR THE PREPARATION THEREOF, COMPOSITIONS, USES, METHODS FOR TREATMENT USING SAME, AND KITS | EUROFARMA LABORATÓRIOS S.A. (BR) | 2023-02-09 | — | — | WO | disclosed |
| US-11225655-B2 | Bi-functional complexes and methods for making and using such complexes | NUEVOLUTION A/S (DK) | 2022-01-18 | — | — | US | disclosed |
| US-20130281324-A1 | BI-FUNCTINAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | NUEVOLUTION A/S (DK) | 2013-10-24 | — | — | US | disclosed |
| US-8158665-B2 | Farnesoid X receptor agonists | GLAXOSMITHKLINE LLC (US) | 2012-04-17 | — | — | US | disclosed |
| EP-1962838-B1 | FARNESOID X RECEPTOR AGONISTS | GLAXOSMITHKLINE LLC (US) | 2011-09-28 | — | — | EP | disclosed |
| US-20100160398-A1 | Farnesoid X Receptor Agonists | GLAXOSMITHKLINE LLC | 2010-06-24 | — | — | US | disclosed |
| US-7705028-B2 | Farnesoid X receptor agonists | GLAXOSMITHKLINE LLC (US) | 2010-04-27 | — | — | US | disclosed |
| EP-1962838-A2 | FARNESOID X RECEPTOR AGONISTS | Smithkline Beecham Corporation (US) | 2008-09-03 | — | — | EP | disclosed |
| US-20080167356-A1 | FARNESOID X RECEPTOR AGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 2008-07-10 | — | — | US | disclosed |
| WO-2007076260-A2 | FARNESOID X RECEPTOR AGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 2007-07-05 | — | — | WO | disclosed |
| US-7226945-B2 | Estrogen receptor-β ligands | ASTRAZENECA AB (SE) | 2007-06-05 | — | — | US | disclosed |
| US-20050043350-A9 | Estrogen Receptor-beta ligands | ASTRAZENECA AB (SE) | 2005-02-24 | — | — | US | disclosed |
| US-20040039015-A1 | Estrogen Receptor-beta ligands | BARLAAM BERNARD (FR) | 2004-02-26 | — | — | US | disclosed |
| EP-1326593-A1 | ESTROGEN RECEPTOR-$g(b) LIGANDS | AstraZeneca AB (SE) | 2003-07-16 | — | — | EP | disclosed |
| WO-2002030407-A1 | ESTROGEN RECEPTOR-β LIGANDS | ASTRAZENECA AB (SE) | 2002-04-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050043350-A9 | Estrogen Receptor-beta ligands | ESR2, GPER1, ESR1 | CA12 2609/4885CA1 2806/4885CA9 3770/4885 |
| US-20080167356-A1 | FARNESOID X RECEPTOR AGONISTS | NR1H4, NR1H3, NR1H2 | CA12 4667/4885CA1 4634/4885CA9 4354/4885 |
| US-20040039015-A1 | Estrogen Receptor-beta ligands | ESR2, GPER1, ESRRG | CA12 1789/4885CA1 1819/4885CA9 3565/4885 |
| US-20100160398-A1 | Farnesoid X Receptor Agonists | NR1H4, NR1H3, NR1H2 | CA12 4667/4885CA1 4634/4885CA9 4354/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.